Avalyn Pharma (NASDAQ:AVLN) Trading Up 5.3% – Should You Buy?

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) traded up 5.3% on Friday . The company traded as high as $27.76 and last traded at $27.04. Approximately 63,435 shares traded hands during trading, a decline of 84% from the average session volume of 400,026 shares. The stock had previously closed at $25.68.

Analyst Upgrades and Downgrades

Several research firms have commented on AVLN. Morgan Stanley began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price on the stock. Zacks Research raised Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Guggenheim initiated coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price objective for the company. Finally, Jefferies Financial Group began coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $59.00.

Avalyn Pharma Stock Up 10.2%

The stock has a fifty day moving average price of $28.88. The firm has a market cap of $1.25 billion and a P/E ratio of -1.30.

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Activity at Avalyn Pharma

In related news, Director Jill Carroll bought 277,778 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the purchase, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.